As reported in December 2025, data from the aleniglipron clinical program included 36-week data from the core Phase 2b ACCESS study and the exploratory ACCESS II study, as well as interim data from ...

The man is charged with "conspiracy to introduce misbranded drugs into interstate commerce with intent to defraud and mislead." ...

Consensus Offers Clinicians Structured Guidance on When and How to Reassess, Taper, or Discontinue Psychotropic ...

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.

The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...

The FDA is reportedly considering broadening the types of drugs that can be sold without a prescription, a move some pharmacy ...

AIOMEGA® announced the first prescribed clinical use of AIO BREATHE® mandibular repositioning device, FDA-cleared for ...

Experts advise against turning to GLP-1 drugs such as Wegovy and Mounjaro to suppress appetite ...

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...